FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 07/2024”. The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.
As of the end of July 2024 we identify the following current VC trends in Europe:
-
Total Healthcare & Life Sciences funding reached EUR 5,279m
-
Biotech received 58% of the total investment volume (EUR 3,076m) with oncology being the leading indication (50%)
-
In July, Flo Health (United Kingdom) secures the highest transaction volume with EUR 184m, followed by Catalym (Germany) with EUR 139m and Myricx Bio (United Kingdom) with EUR 106m
-
General Atlantic (United States) is the most active investor (by deal volume), followed by European Innovation Council Fund (Belgium) and Forbion (Netherlands)
To access the full report, please click here.
FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 03/2025 published
FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 09/2024 published